AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC)'s acquisition by Eli Lilly for up to $3.8 billion reinforces growing interest from large pharmaceutical companies in psychedelic-based therapies, according to analysts at Jefferies, who believe that the deal reflects increasing momentum driven by advancing clinical data and an improving regulatory backdrop.
The acquisition, previously announced by Lilly, values AtaiBeckley at $6.75 per share in cash, or about $2.8 billion in equity, plus a contingent value right of up to $2.50 per share, worth roughly $1 billion if certain milestones are achieved.
Jefferies wrote that the transaction "supports our view Big Pharma's interest in the space is rising as sponsors continue to deliver compelling Phase II/III data in various hard-to-treat $1 billion-plus mental health disorders."
The analysts highlighted AtaiBeckley's lead candidate, BPL-003, an intranasal formulation of 5-MeO-DMT being developed for treatment-resistant depression (TRD), as a key driver of the deal. They noted the therapy has generated "one of the most profound psychedelic datasets in Phase II" and said successful Phase III results by early 2029 could support a commercial opportunity exceeding $1 billion to $2 billion.
Jefferies noted that BPL-003 received the FDA's Breakthrough Therapy Designation in October 2025 following positive Phase IIb data in TRD. The analysts said they remain confident in the program's prospects as two Phase III studies are launched, with topline data expected by early 2029.
Beyond BPL-003, Jefferies pointed to additional pipeline catalysts, including Phase IIb data expected in the fourth quarter of 2026 for VLS-01, a buccal film formulation of DMT for TRD, and further development of EMP-01, an oral R-MDMA therapy being studied for social anxiety disorder.
The firm also argued that investor sentiment toward psychedelic medicines continues to strengthen, citing encouraging clinical trial results across multiple developers, improving regulatory support, and growing validation of the commercial model.
Jefferies wrote that key opinion leaders believe psychedelics could represent the "biggest change" in psychiatry and potentially a "paradigm shift," adding that patient demand already appears "insatiable."
The analysts also pointed to recent regulatory developments, including the FDA's publication of final guidance on psychedelic drug development, planned public discussions later this year, and the agency's use of breakthrough designations and special protocol assessments.
Commercially, Jefferies said Johnson & Johnson (NYSE:JNJ)'s Spravato, which has reached an annualized revenue run rate above $2.3 billion in treatment-resistant depression, demonstrates the viability of in-clinic psychedelic therapies. The analysts believe BPL-003 and VLS-01 could fit into a similar two-hour treatment model.
Looking ahead, Jefferies expects additional placebo-controlled Phase II and Phase III data, together with potential future approvals, to further increase industry and investor attention on the psychedelic medicine space.
Shares of AtaiBeckley surged more than 33% on Thursday to close at $7.15.